MM-092: Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Elderly Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis

Background In the Phase 3 IKEMA study (NCT03275285) prespecified interim analysis, isatuximab (Isa) carfilzomib (K) and dexamethasone (d) (Isa-Kd) significantly improved progression-free survival (PFS) vs Kd in relapsed multiple myeloma (RMM) patients (HR 0.531; 99% CI, 0.318–0.889; P=0.0007). This IKEMA subgroup analysis examined efficacy and safety in elderly patients. Methods Patients with 1–3 prior lines of therapy were randomized 3:2 to receive Isa-Kd (n=179) or Kd (n=123). Primary end point was PFS. We compared outcomes in patients Results 302 randomized patients: 28.5% ≥70 years (Isa-Kd: 29.1%; Kd: 27.6%). Consistent with overall population, Isa-Kd improved PFS independently of age: Conclusions Addition of Isa to Kd improved PFS and quality of response in elderly patients, with manageable safety profile, consistent with benefit observed in overall IKEMA study population. Isa-Kd is a new treatment option for elderly RMM patients.